ORCID
0009-0004-4995-841X (Ormaza-Vera), 0000-0002-6783-1904 (Enos)
Document Type
Editorial
Publication Date
2026
DOI
10.1016/j.jdcr.2026.07.008
Publication Title
JAAD: Case Reports
Volume
75
Pages
252-254
Abstract
[Introduction] To the Editor: The development of the glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) and the dual glucose-dependent insulinotropic polypeptide/GLP-1RAs is revolutionizing the management of metabolic disease. Perhaps most impressive is that their clinical significance extends far beyond their approved indications and touches seemingly every organ system, even the skin.
Rights
© 2026 The Authors.
This is an open access article under the Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Original Publication Citation
Ormaza-Vera, A., & Enos, C. W. (2026). Glucagon-like peptide-1-based therapies and the intersection of metabolic and skin disease. JAAD: Case Reports, 75, 252-254. https://doi.org/10.1016/j.jdcr.2026.07.008
Repository Citation
Ormaza-Vera, A., & Enos, C. W. (2026). Glucagon-like peptide-1-based therapies and the intersection of metabolic and skin disease. JAAD: Case Reports, 75, 252-254. https://doi.org/10.1016/j.jdcr.2026.07.008
Included in
Cardiovascular Diseases Commons, Chemicals and Drugs Commons, Dermatology Commons, Rehabilitation and Therapy Commons